Does the media prefer ABVX or AUPH?

In the previous week, Abivax had 2 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 10 mentions for Abivax and 8 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.95 beat Abivax's score of 0.34 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aurinia Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AUPH or QGEN?

In the previous week, Aurinia Pharmaceuticals had 5 more articles in the media than Qiagen. MarketBeat recorded 8 mentions for Aurinia Pharmaceuticals and 3 mentions for Qiagen. Aurinia Pharmaceuticals' average media sentiment score of 0.95 beat Qiagen's score of 0.72 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AUPH or IBRX?

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than ImmunityBio. MarketBeat recorded 8 mentions for Aurinia Pharmaceuticals and 7 mentions for ImmunityBio. Aurinia Pharmaceuticals' average media sentiment score of 0.95 beat ImmunityBio's score of 0.05 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AUPH or NUVL?

In the previous week, Nuvalent had 32 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 40 mentions for Nuvalent and 8 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.95 beat Nuvalent's score of 0.19 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 14 Very Positive mention(s) 5 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Aurinia Pharmaceuticals (AUPH) Competitors

$15.66 -0.12 (-0.76%)

Closing price 04:00 PM Eastern

Extended Trading

$15.76 +0.10 (+0.61%)

As of 07:40 PM Eastern

Compare

AUPH vs. ABVX, QGEN, IBRX, NUVL, and PRAX

Should you buy Aurinia Pharmaceuticals stock or one of its competitors? MarketBeat compares Aurinia Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aurinia Pharmaceuticals include Abivax (ABVX), Qiagen (QGEN), ImmunityBio (IBRX), Nuvalent (NUVL), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.

How does Aurinia Pharmaceuticals compare to Abivax?

Abivax (NASDAQ:ABVX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Aurinia Pharmaceuticals has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Aurinia Pharmaceuticals	$283.05M	7.11	$287.20M	$2.17	7.22

47.9% of Abivax shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Abivax's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%

Abivax currently has a consensus price target of $130.08, indicating a potential upside of 32.69%. Aurinia Pharmaceuticals has a consensus price target of $17.25, indicating a potential upside of 10.15%. Given Abivax's stronger consensus rating and higher probable upside, equities research analysts clearly believe Abivax is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Abivax has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

In the previous week, Abivax had 2 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 10 mentions for Abivax and 8 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.95 beat Abivax's score of 0.34 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurinia Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aurinia Pharmaceuticals beats Abivax on 10 of the 15 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Qiagen?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Qiagen has higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.11	$287.20M	$2.17	7.22
Qiagen	$2.09B	3.65	$424.88M	$1.91	19.39

Aurinia Pharmaceuticals has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Aurinia Pharmaceuticals presently has a consensus target price of $17.25, indicating a potential upside of 10.15%. Qiagen has a consensus target price of $44.98, indicating a potential upside of 21.46%. Given Qiagen's stronger consensus rating and higher probable upside, analysts clearly believe Qiagen is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Qiagen's net margin of 19.16%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Qiagen	19.16%	14.40%	8.40%

In the previous week, Aurinia Pharmaceuticals had 5 more articles in the media than Qiagen. MarketBeat recorded 8 mentions for Aurinia Pharmaceuticals and 3 mentions for Qiagen. Aurinia Pharmaceuticals' average media sentiment score of 0.95 beat Qiagen's score of 0.72 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Aurinia Pharmaceuticals beats Qiagen on 9 of the 17 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to ImmunityBio?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Aurinia Pharmaceuticals has a net margin of 99.97% compared to ImmunityBio's net margin of -606.15%. Aurinia Pharmaceuticals' return on equity of 26.62% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
ImmunityBio	-606.15%	N/A	-59.53%

Aurinia Pharmaceuticals has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, meaning that its share price is 97% less volatile than the broader market.

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than ImmunityBio. MarketBeat recorded 8 mentions for Aurinia Pharmaceuticals and 7 mentions for ImmunityBio. Aurinia Pharmaceuticals' average media sentiment score of 0.95 beat ImmunityBio's score of 0.05 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 69.5% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aurinia Pharmaceuticals presently has a consensus price target of $17.25, suggesting a potential upside of 10.15%. ImmunityBio has a consensus price target of $14.20, suggesting a potential upside of 103.44%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Aurinia Pharmaceuticals has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.11	$287.20M	$2.17	7.22
ImmunityBio	$113.29M	64.53	-$351.40M	-$0.85	N/A

Summary

Aurinia Pharmaceuticals beats ImmunityBio on 11 of the 16 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Nuvalent?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 5.0% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Aurinia Pharmaceuticals currently has a consensus target price of $17.25, suggesting a potential upside of 10.15%. Nuvalent has a consensus target price of $131.15, suggesting a potential upside of 6.32%. Given Aurinia Pharmaceuticals' higher possible upside, equities analysts plainly believe Aurinia Pharmaceuticals is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nuvalent	1 Sell rating(s)	11 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.35

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Nuvalent's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Nuvalent	N/A	-40.11%	-35.43%

Aurinia Pharmaceuticals has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

In the previous week, Nuvalent had 32 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 40 mentions for Nuvalent and 8 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.95 beat Nuvalent's score of 0.19 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	14 Very Positive mention(s)	5 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.11	$287.20M	$2.17	7.22
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Summary

Aurinia Pharmaceuticals beats Nuvalent on 11 of the 15 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Praxis Precision Medicines currently has a consensus price target of $572.72, indicating a potential upside of 137.98%. Aurinia Pharmaceuticals has a consensus price target of $17.25, indicating a potential upside of 10.15%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, equities research analysts plainly believe Praxis Precision Medicines is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Praxis Precision Medicines has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Praxis Precision Medicines' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%

In the previous week, Praxis Precision Medicines had 2 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 10 mentions for Praxis Precision Medicines and 8 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.95 beat Praxis Precision Medicines' score of 0.25 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurinia Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurinia Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	784.75	-$303.27M	-$13.37	N/A
Aurinia Pharmaceuticals	$283.05M	7.11	$287.20M	$2.17	7.22

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Aurinia Pharmaceuticals beats Praxis Precision Medicines on 9 of the 17 factors compared between the two stocks.

Get Aurinia Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUPH vs. The Competition

Export

Metric	Aurinia Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.03B	$2.96B	$6.50B	$11.95B
Dividend Yield	N/A	1.77%	2.67%	5.61%
P/E Ratio	7.22	12.38	20.85	21.87
Price / Sales	7.11	289.23	500.87	105.21
Price / Cash	15.57	56.16	43.05	54.72
Price / Book	3.55	3.88	10.43	6.70
Net Income	$287.20M	$75.85M	$3.56B	$337.26M
7 Day Performance	-0.06%	-1.87%	-1.39%	-1.41%
1 Month Performance	2.82%	-6.20%	0.86%	1.15%
1 Year Performance	92.15%	12.60%	19.42%	22.61%

Aurinia Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUPH Aurinia Pharmaceuticals	2.9644 of 5 stars	$15.66 -0.8%	$17.25 +10.2%	+93.9%	$2.03B	$283.05M	7.22	300	Positive News
ABVX Abivax	3.2742 of 5 stars	$101.53 flat	$130.08 +28.1%	+1,216.9%	$8.09B	N/A	N/A	61
QGEN Qiagen	4.6233 of 5 stars	$36.28 -1.1%	$44.98 +24.0%	-22.3%	$7.56B	$2.09B	18.95	5,654	Short Interest Decrease
IBRX ImmunityBio	2.9961 of 5 stars	$7.17 +3.6%	$14.20 +98.0%	+110.8%	$7.25B	$113.29M	N/A	590
NUVL Nuvalent	1.8476 of 5 stars	$88.49 -2.7%	$141.24 +59.6%	+62.0%	$7.18B	N/A	N/A	40	Trending News Analyst Downgrade Insider Trade Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUPH) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aurinia Pharmaceuticals (AUPH) Competitors

AUPH vs. ABVX, QGEN, IBRX, NUVL, and PRAX

How does Aurinia Pharmaceuticals compare to Abivax?

Summary

How does Aurinia Pharmaceuticals compare to Qiagen?

Summary

How does Aurinia Pharmaceuticals compare to ImmunityBio?

Summary

How does Aurinia Pharmaceuticals compare to Nuvalent?

Summary

How does Aurinia Pharmaceuticals compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH vs. The Competition

Aurinia Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aurinia Pharmaceuticals (AUPH) Competitors

AUPH vs. ABVX, QGEN, IBRX, NUVL, and PRAX

How does Aurinia Pharmaceuticals compare to Abivax?

Which has stronger valuation & earnings, ABVX or AUPH?

Do institutionals and insiders believe in ABVX or AUPH?

Is ABVX or AUPH more profitable?

Do analysts recommend ABVX or AUPH?

Which has more volatility & risk, ABVX or AUPH?

Does the media prefer ABVX or AUPH?

Summary

How does Aurinia Pharmaceuticals compare to Qiagen?

Which has stronger earnings & valuation, AUPH or QGEN?

Which has more volatility & risk, AUPH or QGEN?

Do analysts rate AUPH or QGEN?

Is AUPH or QGEN more profitable?

Does the media prefer AUPH or QGEN?

Do institutionals & insiders hold more shares of AUPH or QGEN?

Summary

How does Aurinia Pharmaceuticals compare to ImmunityBio?

Is AUPH or IBRX more profitable?

Which has more volatility and risk, AUPH or IBRX?

Does the media favor AUPH or IBRX?

Do institutionals and insiders hold more shares of AUPH or IBRX?

Do analysts rate AUPH or IBRX?

Which has stronger earnings & valuation, AUPH or IBRX?

Summary

How does Aurinia Pharmaceuticals compare to Nuvalent?

Do institutionals & insiders hold more shares of AUPH or NUVL?

Do analysts rate AUPH or NUVL?

Is AUPH or NUVL more profitable?

Which has more risk & volatility, AUPH or NUVL?

Does the media refer more to AUPH or NUVL?

Which has better valuation & earnings, AUPH or NUVL?

Summary

How does Aurinia Pharmaceuticals compare to Praxis Precision Medicines?

Do analysts prefer PRAX or AUPH?

Which has more volatility & risk, PRAX or AUPH?

Is PRAX or AUPH more profitable?

Does the media favor PRAX or AUPH?

Which has preferable valuation & earnings, PRAX or AUPH?

Do insiders and institutionals hold more shares of PRAX or AUPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH vs. The Competition

Aurinia Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools